Newsroom

Sorted by: Latest
-

BeOne Medicines gibt die Zulassung durch die US-amerikanische FDA für eine auf TEVIMBRA basierende Therapie zur Erstlinienbehandlung von HER2-positiver GEA bekannt

SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, gab heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA) den ergänzenden Antrag auf Zulassung eines biologischen Präparats (sBLA) für TEVIMBRA® (Tislelizumab) in Kombination mit ZIIHERA® (Zanidatamab) und einer Chemotherapie zur Erstlinienbehandlung erwachsener Patienten mit inoperablem, lokal fortgeschrittenem oder metastasier...
-

BeOne Medicines anuncia la aprobación de la FDA de EE. UU. de un régimen basado en TEVIMBRA para el tratamiento de primera línea del adenocarcinoma gastroesofágico HER2+

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global de oncología, anunció hoy que la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó la solicitud complementaria de licencia de productos biológicos (sBLA, por sus siglas en inglés) para TEVIMBRA® (tislelizumab) en combinación con ZIIHERA® (zanidatamab) y quimioterapia, para el tratamiento de primera línea para pacientes adulto...
-

Samenvatting: BeOne Medicines kondigt goedkeuring door Amerikaanse FDA aan voor een op TEVIMBRA gebaseerd behandelregime bij eerstelijnsbehandeling van HER2+ GEA

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een wereldwijd oncologiebedrijf, heeft vandaag bekendgemaakt dat de Amerikaanse Food and Drug Administration (FDA) goedkeuring heeft verleend voor de aanvullende aanvraag voor een vergunning voor een biologisch geneesmiddel (sBLA) voor TEVIMBRA® (tislelizumab) in combinatie met ZIIHERA® (zanidatamab) en chemotherapie. Het betreft de eerstelijnsbehandeling van volwassen patiënten met niet-resectabe...
-

BeOne Medicines annonce l’autorisation par la FDA américaine d’un traitement à base de TEVIMBRA pour le GEA HER2+ en première intention

SAN CARLOS, Californie--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq : ONC ; HKEX : 06160 ; SSE : 688235), une société internationale spécialisée en oncologie, a annoncé aujourd’hui que la Food and Drug Administration (FDA) américaine avait approuvé la demande complémentaire d’autorisation de mise sur le marché (sBLA) pour TEVIMBRA® (tislelizumab) en association avec ZIIHERA® (zanidatamab) et une chimiothérapie pour le traitement de première intention des patients adultes atteints d’un adénoca...
-

Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has released a new edition of the company’s rural health report: The State of Rural Hospitals and Cardiovascular Care....
-

Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate in the Nasdaq X LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, in San Francisco, CA.Nasdaq is partnering with LD Micro to host 25 curated public companies, each delivering a 15-minute presentation to a room of institutional investors within the Nas...
-

Jim Fish to Retire from WM; John Morris Named as Next CEO

HOUSTON--(BUSINESS WIRE)--WM (NYSE: WM) announced that Jim Fish, Chief Executive Officer and a member of the Board of Directors, has advised the Board of his plan to retire from WM and resign from the Board, following more than a decade of distinguished service in those roles and more than 25 years with the company. In continuation of WM’s robust succession planning process, the Board of Directors has appointed WM President John Morris to the position of President and Chief Executive Officer, e...
-

Priority Commerce Announces Acquisition of IntelliPay

ALPHARETTA, Ga.--(BUSINESS WIRE)--Priority Technology Holdings, Inc. (NASDAQ: PRTH) (“Priority Commerce” or the “Company”) today announced it has entered into a membership interest purchase agreement to acquire IntelliPay, whose software enables government agencies, educational institutions, and healthcare organizations to securely accept and manage payments.The acquisition will establish Priority Commerce Government, extending the company's enterprise payments business into the public sector. P...
-

Limoneira to Announce Third Quarter 2026 Financial Results on September 9, 2026

SANTA PAULA, Calif.--(BUSINESS WIRE)--Limoneira Company (the “Company” or “Limoneira”) (Nasdaq: LMNR), a diversified lemon and avocado growing and lemon packing company with related agribusiness activities and real estate development operations, announced today it will release financial results for the third quarter ended July 31, 2026, on Wednesday, September 9, 2026, after the market close. The Company will host a conference call to discuss its financial results on September 9, 2026, at 1:30...
-

U.S. Bancorp | BTIG Appoints Mangesh Ghogre as Managing Director, Metals & Mining Coverage

NEW YORK--(BUSINESS WIRE)--BTIG, a U.S. Bancorp company, announced today the appointment of Mangesh Ghogre as a Managing Director within the firm’s Industrials Investment Banking group, where he will focus on Metals and Mining coverage. “We are excited to welcome Mangesh to BTIG,” said Jon Dever, Head of Investment Banking at U.S. Bancorp | BTIG. “He brings deep knowledge of the metals and mining landscape and a strong background advising companies on strategic initiatives and financing solutio...